[go: up one dir, main page]

AR052774A1 - Inmunoterapia para trastornos autoinmunes - Google Patents

Inmunoterapia para trastornos autoinmunes

Info

Publication number
AR052774A1
AR052774A1 ARP050104244A ARP050104244A AR052774A1 AR 052774 A1 AR052774 A1 AR 052774A1 AR P050104244 A ARP050104244 A AR P050104244A AR P050104244 A ARP050104244 A AR P050104244A AR 052774 A1 AR052774 A1 AR 052774A1
Authority
AR
Argentina
Prior art keywords
immunotherapy
autoimmune disorders
autoimmune diseases
agents
cell depletion
Prior art date
Application number
ARP050104244A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR052774A1 publication Critical patent/AR052774A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones y métodos de tratamiento de enfermedades autoinmunes. Uso de agentes de deplecion de células B y conjugados de droga citotoxica/agente de deplecion de células B para el tratamiento de enfermedades autoinmunes. Terapias combinadas y composiciones para tratar enfermedades autoinmunes que incluyen a los agentes de deplecion de células B, conjugados y/o agentes anti-citoquinna.
ARP050104244A 2004-10-08 2005-10-07 Inmunoterapia para trastornos autoinmunes AR052774A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61664704P 2004-10-08 2004-10-08
US68600105P 2005-06-01 2005-06-01

Publications (1)

Publication Number Publication Date
AR052774A1 true AR052774A1 (es) 2007-04-04

Family

ID=36148997

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104244A AR052774A1 (es) 2004-10-08 2005-10-07 Inmunoterapia para trastornos autoinmunes

Country Status (13)

Country Link
US (2) US20070264257A1 (es)
EP (1) EP1796735A4 (es)
JP (1) JP2008515926A (es)
AR (1) AR052774A1 (es)
AU (1) AU2005295041A1 (es)
BR (1) BRPI0516531A (es)
CA (1) CA2582919A1 (es)
GT (1) GT200500283A (es)
MX (1) MX2007004049A (es)
PE (1) PE20060972A1 (es)
SV (1) SV2006002258A (es)
TW (1) TW200630106A (es)
WO (1) WO2006042240A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CA2612937C (en) * 2005-07-22 2014-05-06 Amgen Inc. Concentrated protein lyophilates, methods, and uses
IL282138B2 (en) 2005-08-24 2024-01-01 Immunogen Inc Process for preparing purified drug conjugates
HRP20140172T1 (hr) * 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
JP2008105953A (ja) * 2006-10-23 2008-05-08 Kyoto Sangyo Univ Ｂ細胞傷害抑制剤
DK2465541T3 (en) 2007-05-22 2018-09-17 Wyeth Llc improved methods for producing hydrazides
US20100303813A1 (en) * 2007-06-08 2010-12-02 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
EP3605088A1 (en) 2008-04-09 2020-02-05 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP6049163B2 (ja) * 2008-07-21 2016-12-21 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 改善された治療上の特徴のための抗体の構造変異体
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
RS58810B1 (sr) 2009-06-03 2019-07-31 Immunogen Inc Metodi konjugacije
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
JP4495776B1 (ja) 2009-07-30 2010-07-07 日本製薬株式会社 融合蛋白質
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
SMT201900114T1 (it) 2011-03-29 2019-02-28 Immunogen Inc Preparazione di coniugati maytansinoide-anticorpo mediante un processo a fase unica
BR112014006822B1 (pt) * 2011-09-22 2021-05-18 Amgen Inc. Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l
NZ707091A (en) 2012-10-04 2018-12-21 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
RU2702108C2 (ru) 2013-07-16 2019-10-04 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
US20160143866A1 (en) * 2014-11-21 2016-05-26 Eli D. Ehrenpreis Combination Therapy for Administration of Monoclonal Antibodies
JP6861418B2 (ja) 2015-09-02 2021-04-28 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
MY186016A (en) 2015-09-25 2021-06-14 Genentech Inc Anti-tigit antibodies and methods of use
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
CN115054587B (zh) * 2022-05-12 2023-11-21 山东大学 一种胎盘靶向纳米药物的制备及在妊娠合并自身免疫性疾病治疗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
EP1485130A4 (en) * 2002-02-21 2006-11-22 Univ Duke REAGENTS AND THERAPEUTIC METHODS OF AUTOIMMUNE DISEASES
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CN103833854B (zh) * 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins

Also Published As

Publication number Publication date
WO2006042240A3 (en) 2006-09-21
EP1796735A2 (en) 2007-06-20
GT200500283A (es) 2006-05-08
US20070264257A1 (en) 2007-11-15
CA2582919A1 (en) 2006-04-20
EP1796735A4 (en) 2007-12-12
WO2006042240A2 (en) 2006-04-20
JP2008515926A (ja) 2008-05-15
US20110027273A1 (en) 2011-02-03
AU2005295041A1 (en) 2006-04-20
SV2006002258A (es) 2006-09-19
PE20060972A1 (es) 2006-12-03
MX2007004049A (es) 2007-05-24
BRPI0516531A (pt) 2008-09-09
TW200630106A (en) 2006-09-01

Similar Documents

Publication Publication Date Title
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
DOP2017000177A (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY29283A1 (es) Anticuerpos ab(beta)usados en mejorar la cognicion
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
IL181473A (en) Antibodies @ people @ against @@@ beta @@ preparations that include them and use them
AR037109A1 (es) Uso de flibanserina
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
MX2009003122A (es) Inhibidores de tirosina cinasa de bruton.
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
TW200509896A (en) Analeptic and drug combinations
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Legal Events

Date Code Title Description
FB Suspension of granting procedure